Anticancer agents continue to dominate the list of newly approved drugs, approximately half
of which are immunotherapies. This trend illustrates the considerable promise of cancer …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

The dynamic interplay between cancer and host immune system often affects the process of
myelopoiesis. As a consequence, tumor‐derived factors sustain the accumulation and …

T-cell activation and dysfunction relies on direct and modulated receptors. Based on their
functional outcome, co-signaling molecules can be divided as co-stimulators and co …

Immune checkpoint inhibitors (ICIs) are starting to transform the treatment for patients with
advanced cancer. The extensive application of these antibodies for various cancer obtains …

Myeloid-derived suppressor cells (MDSCs) are newly identified immature myeloid cells that
are characterized by the ability to suppress immune responses and expand during cancer …

Study of myeloid cells endowed with suppressive activity is an active field of research which
has particular importance in cancer, in view of the negative regulatory capacity of these cells …

Around 15 years ago, imatinib mesylate (Gleevec® or Glivec®, Novartis, Switzerland)
became the very first'targeted'anticancer drug to be clinically approved. This drug constitutes …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …